Mukka Proteins IPO will list on March 7; here are allocation, GMP, and other data

Mukka Proteins IPO will list on March 7; here are allocation, GMP, and other data

Mukka Proteins IPO: On Tuesday, March 5, the Mukka Proteins IPO allotment was finalized. On March 07, the business is anticipated to arrive on Dalal Street. On March 6, the investors who applied for the offering and were allocated shares would get them in their demat account.

Both the registrar’s website and BSE offer the ability to view the allotment. Refunds will be started by Cameo Corporate Services on March 6.

The issuer, in this case, Cameo Corporate Services, is the registrant of the offering and is in charge of the refund and IPO allocation. Investors can visit Cameo India’s website to verify allotment and other information. Where the details can be filled in: To view the allocation status, enter the IPO’s name and PAN card number in the search field.

Mukka Proteins’ shares were commanding a notable grey market premium, standing at Rs 35 or 125% above the issue price of Rs 28. This surge in demand showcased investors’ keen interest in the fish meat company’s IPO, which commenced bidding on February 29 and concluded on March 04. Notably, the IPO was offered within a price band of Rs 26-28. Such a significant grey market premium indicates strong anticipation and enthusiasm among potential investors for the company’s prospects.

Read Also: Gopal Snacks IPO

Mukka Proteins specializes in the production and distribution of fish meal, fish oil, and fish soluble paste, essential ingredients utilized in the formulation of aqua feed, poultry feed, and pet food. Renowned as a pivotal figure in the fish protein sector, the company boasts a wide-reaching presence, with exports spanning across more than 10 countries, including Bahrain, Saudi Arabia, and Chile. This extensive global footprint underscores Mukka Protein’s stature as a leading player in the industry, catering to diverse markets and ensuring the delivery of quality products worldwide.

According to the corporation, the monies raised will be utilized to pay the company’s working capital requirements, investments in Ento Proteins, and other general corporate reasons.